Compare iShares MSCI Taiwan ETF (EWT) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares MSCI Taiwan ETF trades at $114.31 (market cap $12.74B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: iShares MSCI Taiwan ETF is far larger — about 113.6× Inovio Pharmaceuticals Inc's market cap, and iShares MSCI Taiwan ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Taiwan ETF for 52 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| EWT | INO | |
|---|---|---|
Market Cap | $12.74B | $112.19M |
Volume | 8,470,920 | 3,201,278 |
Sector | Broad Market / Factor | Health |
52-Week High | $118.00 | $2.60 |
52-Week Low | $60.03 | $0.66 |
Typical Hold Time | 52 Days | 43 Days |
Enterprise Value | — | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $113.34, down 2.49% on the day, with a bullish technical signal from moving averages despite neutral oscillators. The ETF remains heavily concentrated in Taiwan's semiconductor sector, particularly TSMC, benefiting from strong AI-driven demand. Recent news highlights Taiwan's $20 billion investment in US AI infrastructure and continued institutional interest, though geopolitical tensions with China present ongoing risks.
The outlook for EWT is positive due to Taiwan's critical role in AI semiconductor supply chains and reasonable tech valuations. Key opportunities include sustained AI demand and corporate investments, while risks center on China-Taiwan geopolitical friction and semiconductor cycle volatility. Wall Street maintains a bullish stance given growth-adjusted valuation metrics.
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
